Corcept Therapeutics Incorporated (CORT) — Fair Value Analysis

Base-case fair value (P50): $114.48 · Current price: $114.49 · Verdict: Fairly Valued

The Verdict on CORT

Our Monte Carlo simulations indicate that CORCEPT THERAPEUTICS INC (CORT) is Fairly Valued. CORT's current trading price of $114.49 is remarkably close to our median fair value (P50) of $114.48, derived from thousands of forward-looking scenarios designed to model the company’s intrinsic worth. This translates to an -0.0%, aligning squarely with our 'Fairly Valued' assessment. This near equilibrium suggests the market has largely priced in CORT's current fundamentals and future prospects as modeled.

How CORT stacks up against peers

Relative to its sector, CORT holds an average quality tier, suggesting its operational and financial health is neither a significant advantage nor disadvantage compared to competitors. This average standing implies that while CORT isn't significantly overvalued or undervalued based on its intrinsic profile, its $114.49 accurately reflects this competitive positioning according to our models. The lack of significant upside or downside potential indicated by the -0.0% underscores that CORT's valuation is largely in line with its peer group's risk-reward profile and market expectations.

What this means for investors

For investors, CORT's 'Fairly Valued' verdict, underpinned by its average quality tier and the minimal -0.0% between its $114.49 and $114.48, suggests that significant alpha from current levels is less likely in the near term based on intrinsic valuation. While a $114.49 close to the $114.48 indicates the market has largely priced in CORT's fundamentals, disciplined investors may seek deeper insights into its various upside and downside scenarios. Sign up for FairCurve to see the full bear/bull distribution for CORT and track its fair value as new fundamentals are released.